Environmental Risk Assessments (ERAs) are a well-established requirement within the regulatory dossier, framed by guidance from authorities such as the European Medicines Agency (EMA) and aligned with broader principles from the International Council for Harmonisation (ICH).
On paper, the process appears structured and predictable. In practice, however, ERA development often reveals a far more complex reality, shaped by:
- product-specific variability
- data limitations
- cross-functional dependencies
- evolving regulatory expectations
In this blog, we explore some of the most common practical challenges organisations encounter when translating ERA guidance into robust and defensible regulatory practice.
Beyond a Purely Regulatory Exercise
One of the most common misconceptions is treating ERA as a purely regulatory deliverable, something to be assembled once development is already well advanced.
In reality, ERA is deeply rooted in scientific interpretation, particularly toxicology. While guidelines define the expected framework, they do not eliminate the need for expert judgement. On the contrary, they assume it.
Every product introduces its own variables, including:
- physicochemical properties
- exposure pathways
- degradation behaviour
- usage patterns
- environmental fate characteristics
As a result, a one-size-fits-all approach rarely withstands detailed regulatory scrutiny. Toxicology expertise plays a central role throughout the process. It supports not only the interpretation of ecotoxicity data, but also:
- study design decisions
- data relevance assessments
- weight-of-evidence approaches
- evaluation of incomplete datasets
Without sufficient toxicological input, organisations may over-rely on:
- default assumptions
- overly conservative scenarios
- generic exposure models
This can ultimately lead to unnecessary complexity, additional regulatory questions, or risk characterisations that do not accurately reflect the product profile.
Challenges in Execution and Data Consistency
Transition from Guideline Interpretation to Execution
One of the most common challenges lies in the transition from guideline interpretation to execution. Requirements such as Phase I and Phase II assessments are clearly described, yet their application depends heavily on the quality and consistency of the underlying data. Early-stage assumptions are sometimes carried forward without sufficient verification, leading to inconsistencies between development phases. In other cases, data gaps are identified late, when timelines are less flexible and remediation becomes more complex. These situations often result in additional questions during submission or the need for rework, both of which can impact overall timelines.
Data Fragmentation
Information relevant to ERA is typically distributed across multiple functions, including nonclinical, CMC, and regulatory teams. Without early alignment, discrepancies can emerge in key parameters such as predicted environmental concentrations or degradation pathways. These inconsistencies are not always immediately visible but may become apparent during regulatory review, where a coherent and traceable rationale is expected. Ensuring that data sources are aligned and assumptions are transparent is therefore not just good practice, it is essential for a defensible assessment.
Lifecycle Dimension of ERA
Another area that tends to be underestimated is the lifecycle dimension of ERA. While initial submissions receive the most attention, environmental considerations do not end at approval since variations or the introduction of generics can trigger the need to revisit the ERA. If the original assessment lacks robustness or clear documentation, updating it can become a resource-intensive exercise. This is particularly relevant in a regulatory environment that is placing increasing emphasis on sustainability and environmental impact, where expectations are likely to evolve rather than diminish.
Towards a More Robust ERA Strategy
Addressing these challenges does not necessarily require a complete overhaul of existing processes. More often, it requires a more integrated and proactive approach.
Early involvement of cross-functional stakeholders, including toxicology experts, can help identify potential gaps before they become critical issues later in development. At the same time:
- clearer data flows
- stronger documentation practices
- transparent assumptions
- improved traceability
…all contribute to more robust and sustainable ERA development.
Recognising the product-specific nature of ERA also enables organisations to adopt more tailored strategies, aligned with both scientific realities and regulatory expectations.
In this context, ERA should not be viewed as a standalone regulatory exercise. It is better understood as a continuous process that evolves alongside:
- product development
- regulatory strategy
- lifecycle management
Guidelines provide the framework, but their successful application ultimately depends on how effectively scientific expertise and regulatory understanding are combined in practice.
When that balance is achieved, ERAs become not only compliant, but also more scientifically robust and operationally sustainable, reducing the risk of delays and facilitating smoother interactions with authorities.
Looking to Go Deeper?
Environmental Risk Assessments continue to evolve as regulatory expectations around sustainability, lifecycle management, and environmental impact become increasingly important across the pharmaceutical industry.
Looking to strengthen your ERA strategy or address complex environmental risk challenges? Our experts support organisations with scientifically robust and regulatory-aligned ERA development throughout the product lifecycle.
关于作者
Sales Specialist Toxicology
Natalia holds a PharmD and a Master's degree in Drug Research, Development and Innovation. With a strong background in business development, her career also includes outstanding contributions as Medical Sales Representative in different companies, such as Abbott. In addition, Natalia has valuable experience in quality assurance from her time at Pfizer and other pharmaceutical manufacturing sites, ensuring compliance with industry standards.
Get Expert Toxicology Assessments
QbD Group offers a set of Toxicology services, for your processes, applications, and equipment. We are EUROTOX certified and are members of AETOX.
Read more订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。